No Data
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments
Amneal Pharmaceuticals (AMRX) said Monday that it has expanded its biosimilar portfolio to eight by adding ADL018, a proposed biosimilar of Novartis' (NVS) Xolair, or omalizumab, to its pipeline. The
Goldman Sachs Sticks to Their Buy Rating for Novartis AG (NOVN)
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Exsilio Therapeutics Launches With $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases
Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, In
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
Nestle Carefully Targets Weight-Loss Drug Users With New Food Line
Last month, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management. The Euro